In addition to SAPONEX and TQL-1055, Adjuvance is able to produce a variety of novel QS-21 saponin adjuvants for research and development efforts. Our synthetic processes provides vaccine developers with adaptability through rationally designed structural variants of QS-21. Using our proprietary chemistry, Adjuvance is able to delete and append portions of saponin adjuvants in a manner that provides a diverse array of unique TiterQuil adjuvants.
Stabilized QS-21 Variants
Stablization of the QS-21’s labile ester linkage vastly improves stability and tolerability.
For example, naturally occurring QS-21 contains two labile ester linkages within the acyl chain that can limit its efficacy and adversely diminish it’s tolerability. In our first generation of TiterQuil adjuvants (TiterQuil 101, 102 & 103), we systematically improved natural QS-21 by strategically replacing these ester linkages, while substantially simplifying the acyl chain (R). These modifications vastly improved stability and tolerability.
Additional VariantsThese QS-21 analogs are just a small portion of the types of adjuvant molecules available through our product platform.
Effecting modifications to portions of naturally occurring saponin adjuvants allows Adjuvance to create an a wide variety of unique adjuvant molecules. TriSST represents a viable solution to the dearth of acceptable vaccine adjuvants. TriSST is a more reliable method of producing the world’s leading adjuvant candidate (QS-21) and is capable of providing an entire portfolio of novel adjuvant molecules with improving stability, toxicity, efficacy and cost profiles. TriSST is an innovative technology whose superiority provides the power, dependability and adaptability necessary to empower current-generation and next-generation vaccine formulations through our SAPONEX and TiterQuil molecules. Click below to learn more about the types of modifications TriSST enables.